REDWOOD CITY, Calif.,
May 26, 2016 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
the company will present results from seven Oncotype DX®
studies at the 2016 American Society of Clinical Oncology (ASCO)
Annual Meeting, which will take place June
3-7 at McCormick Place in Chicago. The results will include:
- Four sub-analyses from the large population-based observational
study based on the Surveillance, Epidemiology, and End Results
(SEER) program of the National Cancer Institute (NCI). Highlights
include two independent presentations by the SEER-NCI investigators
revealing significant disparities in the use of Oncotype DX in
patients with early-stage invasive breast cancer. The primary SEER
Registry study results, presented at the CTRC-AACR San Antonio
Breast Cancer Symposium (SABCS) in December 2015, demonstrated that
Oncotype DX accurately predicts prospective patient outcomes in
more than 42,000 patients, including those with node-negative and
node-positive breast cancer.
- An oral presentation on the clinical use of the Oncotype DX
Breast Recurrence Score™ and patient experiences in invasive breast
cancer, led by investigators at the University
of Michigan;
- Five-year clinical outcomes results from the prospective Phase
III PlanB trial, one of the largest contemporary adjuvant breast
cancer trials in Europe, conducted
by the West German Study Group (WSG); and
- A study of the Oncotype DX Genomic Prostate Score in men with
surgically treated intermediate- and high-risk prostate
cancer.
"Results from the latest breast and prostate cancer studies
highlight the important impact of Oncotype DX in changing the
treatment paradigm for hundreds of cancer patients every day," said
Steven Shak, M.D., chief scientific officer, Genomic Health. "The
breadth and strength of evidence for the clinical utility of
Oncotype DX continue to be uniquely recognized by leading
authorities in cancer. For example, the National Comprehensive
Cancer Network (NCCN), in its updated breast cancer guidelines
regarding node-negative and node-positive patients, specifically
named Oncotype DX as the 'best validated' test for chemotherapy
prediction."
The ASCO abstracts are now available at
http://abstracts.asco.org/. Following are details for each
presentation (all times are in Central Daylight Time):
Saturday, June 4
- Abstract: 6575
Poster Session: Health Services Research and Quality of
Care
Title: "Breast cancer specific survival in patients with
node positive hormone receptor positive invasive breast cancer and
Oncotype DX Recurrence Score results in the SEER database"
Authors: Megan Roberts,
Ph.D.
Location: Hall A
Time: 1-4:30 p.m.
- Abstract: 5049
Poster Session: Genitourinary (Prostate Cancer)
Title: "A 17-gene genomic prostate score (GPS) as a
predictor of biochemical (BCR) and clinical recurrence (CR) in men
with surgically treated intermediate- and high-risk prostate cancer
(PCa)"
Authors: Eric A. Klein,
M.D.
Location: Hall A
Time: 1-4:30 p.m.
- Abstract: 6552
Poster Session: Health Services Research and Quality of
Care
Title: "Compliance with guidelines and factors associated
with ordering the 21-gene breast cancer assay"
Author: Valentina I. Petkov,
M.D., M.P.H.
Location: Hall A
Time: 1-4:30 p.m.
- Abstract: 6553
Poster Session: Health Services Research and Quality of
Care
Title: "Dissemination of 21-gene assay testing among female
breast cancer patients in the US"
Authors: Kathleen Cronin,
Ph.D., M.P.H.
Location: Hall A
Time: 1-4:30 p.m.
Sunday, June 5
- Abstract: 556
Poster Session: Breast Cancer – HER2/ER
Title: "Prognostic impact of 21-Gene Recurrence Score, IHC4,
and central grade in high-risk HR+/HER2− early breast cancer (EBC):
5-year results of the prospective Phase III WSG PlanB trial"
Authors: Oleg Gluz, M.D.
Location: Hall A
Time: 8-11:30 a.m.
- Abstract: 574
Poster Session: Breast Cancer – HER2/ER
Title: "Outcome disparities by age and 21-gene recurrence
score (RS) in hormone receptor positive (HR+) breast cancer
(BC)"
Authors: Valentina I. Petkov,
M.D., M.P.H.
Location: Hall A
Time: 8-11:30 a.m.
Monday, June 6
- Abstract: 6501
Oral Session: Health Services Research and Quality of
Care
Title: "Clinical use of the 21-gene assay and patient
experiences in early-stage breast cancer"
Author: Steven J. Katz, M.D.,
M.P.H.
Location: S100a
Session Time: 9:45 a.m.-12:45
p.m.
Oral Presentation Time: 9:57-10:09
a.m.
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. With
more than 600,000 patients tested in more than 90 countries, the
Oncotype DX tests have redefined personalized medicine by making
genomics a critical part of cancer diagnosis and treatment. To
learn more about Oncotype DX tests, visit www.OncotypeDX.com,
www.mybreastcancertreatment.org
and www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider
of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of cancer, one of the greatest
issues in healthcare today. With its Oncotype IQ™ Genomic
Intelligence Platform, the company is applying its world-class
scientific and commercial expertise and infrastructure to lead the
translation of clinical and genomic big data into actionable
results for treatment planning throughout the cancer patient
journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and
services currently consists of the company's flagship line of
Oncotype DX gene expression tests that have been used to guide
treatment decisions for more than 600,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid and tissue-based tests. The company is
based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties are set forth in
our filings with the Securities and Exchange Commission, including
in our quarterly report on Form 10-Q for the quarter ended
March 31, 2016. These forward-looking
statements speak only as of the date hereof. Genomic Health
disclaims any obligation to update these forward-looking
statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are
trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-B
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-seven-oncotype-dx-studies-at-the-2016-american-society-of-clinical-oncology-annual-meeting-including-additional-prospective-outcomes-analysis-300275292.html
SOURCE Genomic Health, Inc.